

claim 125 to delete the terms "pharmaceutical" and "pharmaceutically acceptable" thus obviating this rejection.

Section 103

Claim 125 stands rejected under 35 U.S.C. § 103, as being unpatentable over Dolle, United States Patent 5,985,838 ("Dolle") and Chapman, United States Patent 5,430,128 ("Chapman"). The Examiner contends that pharmaceutical compositions of claim 125 comprising compounds of claim 105 are obvious over Dolle and Chapman. Applicants traverse.

Applicants have amended claim 125 to recite the elected subject matter only (Group I). As amended, claim 125 no longer encompasses the subject matter objected to by the Examiner. Dolle and Chapman, alone or in combination, neither teach nor suggest applicants' claimed compositions. Accordingly, applicants request that the Examiner withdraw the § 103 rejection.

CONCLUSION

Applicants request that the Examiner enter the amendments presented herein, consider the foregoing remarks, and allow the pending claims to issue.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Min Wang (Reg. No. 51,303)  
Agent for Applicants  
c/o FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, NY 10020  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090

APPENDIX

MARKED UP CLAIM SHOWING AMENDMENTS

125. (amended) A [pharmaceutical]  
composition comprising a compound according to any one  
of claims [102-107 or 118] 102-104 and a  
[pharmaceutically acceptable] carrier.